Unknown PHASE1 INTERVENTIONAL 1-arm NCT01226407

Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile

Phase I Study of CG200745 to Examine the Maximum Tolerate Dose, Pharmacokinetic and Pharmacodynamic Profiles, and Safety Among Patients With Progressive Solid Cancer

Sponsor: CrystalGenomics, Inc.

Conditions Solid Tumour

Interventions CG200745

Updated 6 times since 2017 Last updated: Dec 27, 2012 Started: Sep 30, 2010 Primary completion: Feb 28, 2013 Completion: Feb 28, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Solid Tumour, this trial is ongoing. The trial is conducted by CrystalGenomics, Inc. and has accumulated 6 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE1
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CrystalGenomics, Inc.

Data source: CrystalGenomics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea